Related Experiment Video
Updated: Jun 28, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Comments on: Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with
Rajesh Prasad Jayaswal1, Shailendra Thapliyal2, Rama Kumari Badyal3
1Department of Medical Laboratory Sciences, University Institute of Allied Health Sciences, Chandigarh University, Mohali, Punjab, 140413, India. rpjayaswal.jec@gmail.com.
Abstract:
This correspondence comments on LeVee et al.'s real-world study of neoadjuvant chemo-immunotherapy in early-stage triple-negative breast cancer. We highlight diabetes as a potentially modifiable host-state factor influencing pathologic complete response and propose a metabolic immunotherapy-readiness framework integrating glycaemic control, treatment delivery, endocrine monitoring, and equity-focused implementation. This perspective aims to support globally applicable strategies for improving chemo-immunotherapy effectiveness and access.
Related Concept Videos
Tumor Immunotherapy
Treatment Resistent Cancers
Treatment Resistant Cancers